The decision as to which of the two drugs a patient receives was based on the Combined Positive Score (CPS, proportion of PD-L1-positive tumor and immune cells in relation to all tumor cells, multiplied by 100), with patients with a CPS ≥ 1 receiving pembrolizumab and those with a CPS < 1 receiving nivolumab. Here, CD274 is linked to neoplasm.